The 4888.T stock closed at JPY 560.00 on JPX on 18 Mar 2026, a 35.27% one-day gain on 5,861,100.00 shares traded. This jump followed a wide intraday range from JPY 455.00 to JPY 560.00 and pushed price well above the 50-day average of JPY 341.78. Investors are pricing in progress for Stella Pharma Corporation’s BNCT pipeline, while trading volume was roughly 3.11x the average daily volume, signaling aggressive speculative flows into the biotechnology name in Japan.
4888.T stock price action and volume drivers
Stella Pharma (4888.T) traded 5,861,100.00 shares on the session, compared with an average volume of 1,884,700.00, producing a relative volume of 8.02. The stock opened at JPY 475.00 and closed at JPY 560.00, up from the previous close of JPY 414.00. High volume and a new session high at JPY 560.00 indicate institutional or event-driven interest rather than routine momentum.
Catalysts: BNCT program and upcoming data
Stella Pharma’s pipeline focus on boron neutron capture therapy (BNCT) is the most likely catalyst behind the move in 4888.T stock. The company lists SPM-011 for head and neck cancer and malignant glioma on its site. Analysts and traders watch trial milestones and regulatory updates closely, and the next public earnings-related timeline is the company’s earnings announcement on 2026-05-12.
Fundamentals and valuation for 4888.T stock
Stella Pharma reports EPS of -5.04 and a trailing PE of -95.24, reflecting negative earnings. The company has cash per share JPY 79.10 and book value per share JPY 79.33, with a price-to-book ratio of 6.06. Market capitalization stands at JPY 16,331,996,640.00, but revenue per share is only JPY 28.47, giving a price-to-sales of 16.86. These metrics show high valuation relative to current revenues and persistent operating losses.
Technical indicators and short-term momentum on 4888.T stock
Technicals show an ADX of 49.12, indicating a strong trend, while RSI at 50.22 sits near neutral. Bollinger Bands mid is JPY 438.75 with upper band JPY 513.27, which the stock exceeded intraday. The MACD histogram is -8.06, suggesting momentum divergence despite the price spike. These mixed signals mean buyers are active but momentum may need follow-through to sustain the gain.
Meyka Grade and model forecast for 4888.T stock
Meyka AI rates 4888.T with a score out of 100: Meyka AI rates 4888.T with a score out of 100 70.43 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly price of JPY 302.74, a monthly projection of JPY 291.89, and a three-year projection of JPY 200.73. Compared with the current price of JPY 560.00, the yearly projection implies an -45.94% downside. Forecasts are model-based projections and not guarantees.
Sector context and risks for 4888.T stock
Stella Pharma sits in Healthcare / Biotechnology where the Japanese sector 3M performance is 1.50% and average PE is 23.62. Company-specific risks include negative EPS, long inventory days (days of inventory on hand 3304.72) and negative operating margins (operating profit margin -23.52%). Upside depends on clinical readouts and regulatory clarity for BNCT programs, while downside stems from clinical, funding, or competitive setbacks.
Final Thoughts
4888.T stock’s JPY 560.00 close on JPX on 18 Mar 2026 and the 35.27% rise were driven by heavy volume and BNCT-related interest. Fundamentals show negative EPS (-5.04) and high valuation ratios (P/S 16.86, P/B 6.06) that make the move speculative from a fundamental standpoint. Meyka AI’s forecast model projects JPY 302.74 for the year, implying -45.94% versus today’s price, while a bull scenario could reach JPY 700.00 (+25.00%) and a conservative target sits near JPY 350.00 (-37.50%). Investors should weigh near-term catalysts and the upcoming 2026-05-12 earnings timeline against weak profitability and inventory risk. Meyka AI’s analysis platform flags this as high volatility trading in Japan’s JPX market; forecasts are model-based and not guarantees.
FAQs
What caused the 35.27% move in 4888.T stock on 18 Mar 2026?
The rise came with heavy volume (5,861,100.00 shares) and market interest in Stella Pharma’s BNCT pipeline. Traders reacted to perceived clinical or corporate updates; no formal regulatory release was required to spark speculative buying.
What is Meyka AI’s forecast for 4888.T stock versus the current price?
Meyka AI’s forecast model projects a yearly price of JPY 302.74 versus the current JPY 560.00, implying an estimated downside of -45.94%. Forecasts are model-based projections and not guarantees.
Are Stella Pharma’s fundamentals supportive of the recent rally in 4888.T stock?
Fundamentals show negative EPS (-5.04), P/S 16.86 and P/B 6.06, which do not support an enduring valuation premium. The rally appears catalyst-driven and speculative rather than fundamentally validated.
What timeline should investors watch for 4888.T stock?
Watch the earnings announcement on 2026-05-12 and any BNCT clinical readouts or regulatory updates. These events typically drive price and liquidity in Stella Pharma on JPX.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)